Research map: Precision Warfare in Solid Tumors: Molecular Mechanisms and Emerging Frontiers of Antibody–Drug Conjugates

Back to the article

Papers in this map

  1. Role of hypoxia in cancer therapy by regulating the tumor microenvironment · Xinming Jing · 2019 · 2153 citations · Cited by this paper
  2. Lactylation-Mediated METTL14 Promotes Glycolysis Through Facilitating PGAM1 m6A Methylation in Non-Small Cell Lung Cancer · 2026 · Related
  3. The Different Mechanisms of Cancer Drug Resistance: A Brief Review · Behzad Mansoori · 2017 · 1929 citations · Cited by this paper
  4. Mechanisms and Therapeutic Targeting of the Gut Microbiota-Immune-Brain Axis in Alzheimer’s Disease · 2026 · Related
  5. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer · Aditya Bardia · 2021 · 1674 citations · Cited by this paper
  6. Differences in Shared T Cell receptor α Repertoire Associated with Recognition of Viral Antigens · 2026 · Related
  7. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma · Thomas B. Powles · 2021 · 1236 citations · Cited by this paper
  8. Astragalus Polysaccharide Promotes NLRP3 + Macrophages Polarization via Suppression of OGT in Hepatocellular Carcinoma · 2026 · Related
  9. Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer · Bob T. Li · 2021 · 1033 citations · Cited by this paper
  10. The STING-Inflammasome Axis: Coordinated Immune Regulation and Therapeutic Potential Across Diverse Diseases · 2026 · Related
  11. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma · Hervé Tilly · 2021 · 925 citations · Cited by this paper
  12. UBE2I Alleviates Pyroptosis in Coronary Heart Disease by Promoting the SUMOylation and Degradation of NLRP3 · 2026 · Related
  13. Antibody–Drug Conjugates: A Comprehensive Review · Puregmaa Khongorzul · 2019 · 799 citations · Cited by this paper
  14. HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial · 2026 · Related
  15. Cleavable linkers in antibody–drug conjugates · Jonathan D. Bargh · 2019 · 662 citations · Cited by this paper
  16. Reprogramming the tumor microenvironment: synergistic mechanisms of antibody–drug conjugates and immune checkpoint inhibitors · 2025 · Related
  17. Tuning the Antigen Density Requirement for CAR T-cell Activity · Robbie G. Majzner · 2020 · 610 citations · Cited by this paper
  18. Antibody–drug conjugates in cancer and beyond: progress, promise, and perspectives · 2025 · Related
  19. Hypoxia-targeted drug delivery · Amit Kumar Sharma · 2018 · 555 citations · Cited by this paper
  20. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial · 2026 · Related
  21. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? · Alexander H. Staudacher · 2017 · 550 citations · Cited by this paper
  22. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial · Hope S. Rugo · 2023 · 476 citations · Cited by this paper
  23. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies · Paolo Tarantino · 2021 · 390 citations · Cited by this paper
  24. Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment · Xiaoxiao Sun · 2015 · 356 citations · Cited by this paper
  25. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma · Stephen Maxted Ansell · 2022 · 352 citations · Cited by this paper
  26. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models · Li Fu · 2016 · 341 citations · Cited by this paper
  27. How to select IgG subclasses in developing anti-tumor therapeutic antibodies · Jifeng Yu · 2020 · 271 citations · Cited by this paper
  28. Antibody–drug conjugates in solid tumors: a look into novel targets · Carmen Criscitiello · 2021 · 261 citations · Cited by this paper
  29. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia · Robert J. Kreitman · 2018 · 253 citations · Cited by this paper
  30. Payload diversification: a key step in the development of antibody–drug conjugates · Louise Conilh · 2023 · 252 citations · Cited by this paper
  31. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed · Jessica S. Brown · 2017 · 233 citations · Cited by this paper
  32. Mechanisms of Resistance to Antibody–Drug Conjugates · Frank Loganzo · 2016 · 232 citations · Cited by this paper
  33. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate · Rotimi Sheyi · 2022 · 224 citations · Cited by this paper
  34. Overcoming the biological barriers in the tumor microenvironment for improving drug delivery and efficacy · Yang Zhou · 2020 · 210 citations · Cited by this paper
  35. Resistance to the Antibody–Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity · Carla Ríos‐Luci · 2017 · 200 citations · Cited by this paper
  36. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma · Vânia Hungria · 2024 · 194 citations · Cited by this paper
  37. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer · Ignace B. Vergote · 2024 · 193 citations · Cited by this paper
  38. ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers · Lillian K. Skidmore · 2020 · 166 citations · Cited by this paper
  39. Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency · Dian Su · 2021 · 163 citations · Cited by this paper

Source: OpenAlex (CC0)